AffyMax Overview

  • Founded
  • 2001
Founded
  • Status
  • Public
  • Employees
  • 72
Employees
  • Stock Symbol
  • AFFY
Stock Symbol
  • Share Price
  • $0.02
  • (As of Thursday Closing)

AffyMax General Information

Description

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Contact Information

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 600 Fifth Avenue
  • 2nd Floor
  • New York, NY 10020
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

AffyMax Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.02 $0.03 $0.01 - $0.06 30.4K

AffyMax Financials Summary

In Thousands,
USD
TTM 30-Jun-2014 FY 2013 31-Dec-2013 FY 2012 31-Dec-2012 FY 2011 31-Dec-2011
EV (1,051) 22,390 636,650 120,931
Revenue 42 1,369 94,370 47,720
EBITDA 2,694 (14,316) (90,086) (59,209)
Net Income 2,694 (14,424) (93,412) (61,367)
Total Assets 5,384 7,443 118,217 118,995
Total Debt 0 0 8,844 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

AffyMax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial

AffyMax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for
Pharmaceuticals
New York, NY
72 As of 2015
00000
0.00 0000-00-00
000000000 00000

000000 (

t nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt
0000 000000000
New York, NY
0 As of 0000
00000
0000000000 00000

000000 0

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi
0000 000000000
Toronto, Canada
0 As of 0000
000.00
000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AffyMax Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akelos (Drug Discovery) Angel-Backed New York, NY 0 00000 0000000000 00000
000000 00000000000 Corporation Toronto, Canada 0 000.00 000000000 000.00
0000 Venture Capital-Backed San Diego, CA 0 00000 0000000000 0 00000
0000000 0000000000 Corporation Guilford, CT 00.00 000000000 00.00
000000 000000000 Formerly PE-Backed Germantown, MD 0 000.00 000000000 000.00
You’re viewing 5 of 13 competitors. Get the full list »

AffyMax Executive Team (30)

Name Title Board Seat Contact Info
Mark Thompson Chief Financial Officer, Finance
Grace Shin JD General Counsel
Christine Conroy Senior Vice President, Regulatory Affairs and Quality Assurance
Michael Holfinger Ph.D Vice President
Anne-Marie Duliege MD Chief Medical Officer
You’re viewing 5 of 30 executive team members. Get the full list »

AffyMax Board Members (15)

Name Representing Role Since
Christine van Heek Self Board Member 000 0000
Hollings Renton Self Chairman & Board Member 000 0000
John Orwin Self Board Member 000 0000
You’re viewing 3 of 15 board members. Get the full list »

AffyMax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AffyMax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial